Mumbai based pharma major Lupin Limited (Lupin) recently announced the launch of Favipiravir in India under the brand name Covihalt® for the treatment of mild to moderate COVID-19. Favipiravir has received authorization from the Drug Controller General of India (DCGI) for emergency use. Lupin’s Covihalt® dosage strength has been developed keeping in mind the convenience of administration.

It is available as 200 mg tablets in the form of a strip of 10 tablets and priced at Rs. 49 per tablet.  

Rajeev Sibal, President - India Region Formulations (IRF) commented on this development, “Lupin has always been committed to the fight against life-threatening diseases. COVID-19 is a global pandemic and in India, we are seeing a surge in the number of cases on a daily basis. Covihalt®, Lupin’s Favipiravir drug, is a vital step in this direction. We believe that we can leverage our expertise in managing widespread community diseases like TB to proactively reach patients across India and ensure access to Covihalt® through our strong distribution network and field force.”